Myeloid
United States · $50.0M raised
- Business Model
- B2B
- Total Funding
- $50.0M
- Last Round
- $50.0M Series AJan 2021
- Rounds
- 1
About
Clinical-stage biotech pioneering in vivo mRNA-based multi-immune programming; rebranded as CREATE Medicines.
Summary
Myeloid is a Biotech company based in United States. It has raised $50.0M in total across 1 round, most recently a $50.0M Series A round in Jan 2021. Investors include Newpath Management, 8VC and Hatteras Venture Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2021
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company